Application of sequential multi-disciplinary treatment in the full process management of prostate cancer

doi:10.3877/cma.j.issn.1674-3253.2025.02.005

Abstract

Abstract:

Objective

This article reports a case of localized prostate cancer that progressed to metastatic castration - resistant prostate cancer.The patient experienced three sequential multi - disciplinary therapy （MDT） treatments in the past three years.The article shares the application experience of sequential MDT in prostate cancer management.

Methods

A patient with "5-year post-radical prostatectomy and subsequent endocrine therapy due to biochemical recurrence，resulting in PSA increase" was reviewed.The treatment process and experience were summarized.

Results

The patient initially had localized prostate cancer，underwent surgery and regular follow-up.During follow-up，biochemical recurrence，PSA progression，oligometastatic lesions and multiple metastases occurred.The patient underwent three sequential MDT treatments，receiving adjuvant endocrine therapy，radiotherapy for metastases，novel endocrine therapy and chemotherapy.The patient's condition is currently stable.

Conclusion

The sequential MDT consultation model plays a crucial role in prostate cancer management，providing comprehensive and effective treatment plans for each disease progression.

Key words: Prostate cancer, Multi-disciplinary treatment, Hormone therapy, Full process management

Zhenyang Dong, Min Qu, Yan Wang, Yun Zhang, Xu Gao. Application of sequential multi-disciplinary treatment in the full process management of prostate cancer[J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 152-158.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhqjmnmwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-3253.2025.02.005

https://zhqjmnmwkzz.cma-cmc.com.cn/EN/Y2025/V19/I02/152

Figures/Tables 4

References 29

［1］	Chen WQ，Zeng HM，Zheng RS，et al.Cancer incidence and mortality in China，2007［J］.Chin J Cancer Res，2012，24（1）： 1.DOI：10.1007/s11670-012-0001-6.
［2］	吴洪瀚，范青洪，瓦庆德.前列腺癌骨转移治疗研究进展［J］.遵义医科大学学报，2024，47（4）： 424-431.DOI： 10.14169/j.cnki.zunyixuebao.2024.0052.Wu HH，Fan QH，Wa QD.Progress in bone metastases treatment for prostate cancer［J］.J Zunyi Med Univ，2024，47（4）：424-431.DOI：10.14169/j.cnki.zunyixuebao.2024.0052.
［3］	Sekhoacha M，Riet K，Motloung P，et al.Prostate cancer review：genetics，diagnosis，treatment options，and alternative approaches［J］.Molecules，2022，27（17）： 5730.DOI： 10.3390/molecules27175730.
［4］	张俊彪，王志华.局限性前列腺癌的治疗新进展［J］.现代泌尿生殖肿瘤杂志，2023，15（4）： 193-196.DOI： 10.3870/j.issn.1674-4624.2023.04.001.Zhang JB，Wang ZH.Advances in the treatment of localized prostate cancer［J］.J Mod Urol Reprod Oncol，2023，15（4）： 193-196.DOI：10.3870/j.issn.1674-4624.2023.04.001.
［5］	王雨帆，邰胜，周骏，等.前列腺癌根治术中前列腺尖部及膀胱颈精准解剖与重建对尿控改善的影响［J］.四川大学学报（医学版），2024，55（5）： 1092-1098.DOI： 10.12182/20240960502.Wang YF，Tai S，Zhou J，et al.Impact of precise dissection and reconstruction of the prostatic apex and bladder neck on urinary continence improvement during radical prostatectomy［J］.J Sichuan Univ （Med Sci Ed），2024，55（5）： 1092-1098.DOI：10.12182/20240960502.
［6］	中国抗癌协会泌尿男生殖系肿瘤专业委员会，中国临床肿瘤学会前列腺癌专家委员会，中国肿瘤医院泌尿肿瘤协作组，等.泌尿男生殖系统肿瘤多学科团队诊治组织与实施规范中国专家共识（2020 年版）［J］.中国癌症杂志，2020，30（4）： 313-320.DOI：10.19401/j.cnki.1007-3639.2020.04.012.Chinese Anti-Cancer Association，Committee of Urological and Genitourinary Tumors，Chinese Society of Clinical Oncology，Prostate Cancer Expert Committee，Chinese Oncology Hospital Urological Tumor Collaborative Group，et al.China expert consensus on the organization and implementation of multidisciplinary team diagnosis and treatment of urogenital tumors （2020 edition）［J］.China Oncol，2020，30（4）： 313-320.DOI： 10.19401/j.cnki.1007-3639.2020.04.012.
［7］	中国抗癌协会泌尿男生殖系肿瘤专业委员会前列腺癌学组.前列腺癌骨转移多学科诊疗专家共识（2020 版）［J］.肿瘤防治研究，2020，47（7）： 479-486.DOI： 10.3971/j.issn.1000-8578.2020.20.2020.Prostate Cancer Group，Chinese Anticancer Association Genitourinary Oncology Committee.Expert consensus of multidisciplinary treatment on bone metastasis of prostate cancer （version 2020）［J］.Cancer Res Prev Treat，2020，47（7）： 479-486.DOI： 10.3971/j.issn.1000-8578.2020.20.2020.
［8］	许碧芳，汪紫娟，吴榕英.多学科诊疗护理干预模式对前列腺癌伴冠心病行前列腺癌根治术后的效果［J］.心血管病防治知识，2022，12（11）： 46-50.DOI： 10.3969/j.issn.1672-3015（x）.2022.11.014.Xu Bifang，Wang Zijuan，Wu Rongying The effect of multidisciplinary diagnosis，treatment and nursing intervention model on prostate cancer with coronary heart disease after radical prostatectomy ［J］.Prevent Treat Cardiovasc Dis，2022，12（11）：46-50.DOI：10.3969/j.issn.1672-3015（x）.2022.11.014.
［9］	聂婷，史振峰，周萍，等.跨理论-多学科新型预康复策略改善机器人辅助前列腺癌根治术中青年患者早期转归和生活体验的研究［J］.中国性科学，2023，32（3）： 5-9.DOI： 10.3969/j.issn.1672-1993.2023.03.002.Nie T，Shi ZF，Zhou P，et al.Study on improvement effects of new inter-theorectical and multidisciplinary pre-rehabilitaion strategy on early outcome and life experience in young and middle-aged patients undergoing robot assisted radical prostatectomy［J］.Chin J Hum Sex，2023，32（3）： 5-9.DOI： 10.3969/j.issn.1672-1993.2023.03.002.
［10］	马丹丹，任洁，乔够梅.多学科团队诊疗模式在转移性去势抵抗性前列腺癌患者护理中的研究进展［J］.华南国防医学杂志，2020，34（5）： 366-368，封3.DOI： 10.13730/j.issn.1009-2595.2020.05.019.Ma DD，Ren J，Qiao GM.Research progress of multidisciplinary team diagnosis and treatment model in nursing care of patients with metastatic castration-resistant prostate cancer［J］.Mil Med J South China，2020，34（5）： 366-368，封3.DOI： 10.13730/j.issn.1009-2595.2020.05.019.
［11］	瞿旻，朱焱，塔娜，等.复杂前列腺癌综合诊疗的多学科团队协作全程管理一例［J］.上海医学，2023，46（10）： 687-692.DOI：10.19842/j.cnki.issn.0253-9934.2023.10.008.Qu M，Zhu Y，Tana，et al.A case of multidisciplinary teamwork in the management of complex prostate cancer［J］.Shanghai Med J，2023，46（10）：687-690.DOI：10.19842/j.cnki.issn.0253-9934.2023.10.008.
［12］	Ishemgulov R，Pavlov V，Izmailov A，et al.Stereotactic body radiation therapy using Cyber-Knife in the treatment of patients with localized prostate cancer［J］.Eur Urol Suppl，2019，18（11）： e3439.DOI： 10.1016/s1569-9056（19）34608-1.
［13］	Cheng Q，Butler W，Zhou Y，et al.Pre-existing castration-resistant prostate cancer-like cells in primary prostate cancer promote resistance to hormonal therapy［J］.Eur Urol，2022，81（5）： 446-455.DOI： 10.1016/j.eururo.2021.12.039.
［14］	Nikitas J，Rettig M，Shen J，et al.Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer （SATURN）：primary endpoint results from a phase 2 clinical trial［J］.Eur Urol，2024，85（6）： 517-520.DOI： 10.1016/j.eururo.2024.01.021.
［15］	Xiao-Xue Z ，Hong-Bin M ，Tie-Hua JYM.Actual over 3-year survival after stereotactic body radiation therapy in patients with unresectable intrahepatic cholangiocarcinoma［J］.Clin Transl Oncol，2023，25（3）： 731-738.DOI： 10.1007/s12094-022-02979-5.
［16］	Tilki D，van den Bergh RCN，Briers E，et al.EAU-EANM-ESTROESUR-ISUP-SIOG guidelines on prostate cancer.part II-2024 update： treatment of relapsing and metastatic prostate cancer［J］.Eur Urol，2024，86（2）： 164-182.DOI： 10.1016/j.eururo.2024.04.010.
［17］	Borkowetz A，Hölscher T.Metastasis-directed therapy in prostate cancer［J］.Urologie，2024，63（3）： 225-233.DOI： 10.1007/s00120-024-02281-y.
［18］	Assi T，Rassy E，Farhat F，et al.Docetaxel rechallenge in patients with metastatic prostate cancer： a comprehensive review［J］.Oncol Res Treat，2020，43（6）： 299-306.DOI： 10.1159/000506693.
［19］	Farolfi A，Calderoni L，Mattana F，et al.Current and emerging clinical applications of PSMA PET diagnostic imaging for prostate cancer［J］.J Nucl Med，2021，62（5）： 596-604.DOI： 10.2967/jnumed.120.257238.
［20］	Giri VN，Morgan TM，Morris DS，et al.Genetic testing in prostate cancer management： Considerations informing primary care［J］.CA Cancer J Clin，2022，72（4）： 360-371.DOI： 10.3322/caac.21720.
［21］	Achard V，Putora PM，Omlin A，et al.Metastatic prostate cancer：treatment options［J］.Oncology，2022，100（1）： 48-59.DOI：10.1159/000519861.
［22］	Padhani AR，Lecouvet FE，Tunariu N，et al.METastasis reporting and data system for prostate cancer： practical guidelines for acquisition，interpretation，and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer［J］.Eur Urol，2017，71（1）： 81-92.DOI： 10.1016/j.eururo.2016.05.033.
［23］	Okudan B，Arıcan P，Seven B.Single-photon emission CT combined with spiral CT for early detection and localization of bone metastasis：a review［J］.Curr Med Imaging，2020，16（5）： 507-512.DOI： 10.2174/1573405615666181224143010.
［24］	Eiber M，Maurer T，Souvatzoglou M，et al.Evaluation of hybrid ⁶⁸Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy［J］.J Nucl Med，2015，56（5）： 668-674.DOI： 10.2967/jnumed.115.154153.
［25］	高旭.从PCWG3 共识的更新看去势抵抗性前列腺癌临床诊治的演变［J］.中华泌尿外科杂志，2022，43（12）： 884-888.DOI：10.3760/cma.j.cn112330-20220818-00469.Gao X.Evolution of clinical diagnosis and treatment of denervationresistant prostate cancer from the update of PCWG3 consensus［J］.Chin J Urol，2022，43（12）： 884-888.DOI： 10.3760/cma.j.cn112330-20220818-00469.
［26］	Hellman S，Weichselbaum RR.Oligometastases［J］.J Clin Oncol，1995，13（1）： 8-10.DOI： 10.1200/jco.1995.13.1.8.
［27］	孙奕飞，张劲松，李宁，等.寡转移性前列腺癌诊疗的研究进展［J］.中华泌尿外科杂志，2022，43（2）： 152-155.DOI： 10.3760/cma.j.cn112330-20200418-00304.Sun YF，Zhang JS，Li N，et al.The progress in diagnosis and treatment of oligometastatic prostate cancer［J］.Chin J Urol，2022，43（2）： 152-155.DOI： 10.3760/cma.j.cn112330-20200418-00304.
［28］	高旭，王海峰，王燕，等.基于浏览器/服务器架构的前列腺癌数据库的构建和临床应用［J］.中华泌尿外科杂志，2015，36（9）： 694-698.DOI： 10.3760/cma.j.issn.1000-6702.2015.09.017.Gao X，Wang HF，Wang Y，et al.Construction and clinical application of prostate cancer database （PC-Follow） based on browser/server Schema［J］.Chin J Urol，2015，36（9）： 694-698.DOI： 10.3760/cma.j.issn.1000-6702.2015.09.017.
［29］	Pasoglou V，Larbi A，Collette L，et al.One-step TNM staging of high-risk prostate cancer using magnetic resonance imaging （MRI）：toward an upfront simplified “all-in-one” imaging approach？［J］.Prostate，2014，74（5）： 469-477.DOI： 10.1002/pros.22764.

[1]	Zhaojue Wang, Qingli Zhu, Wenbo Li, Hong Yang, Jiaming Qian, Jianchu Li. Current situation of implementation of ultrasound in multidisciplinary treatment of inflammatory bowel disease in China [J]. Chinese Journal of Medical Ultrasound (Electronic Edition), 2025, 22(02): 131-138.
[2]	Yonghong Li, Jun Wang, Hengjun Xiao. Interpretation updates of the 2025 NCCN Guidelines on diagnosis and treatment for prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 129-133.
[3]	Haowei Qiu, Zhen Xu, Zexiu Xiao, Yan Xia, Gaofeng Zha, Jun Pang. Updates of mRNA vaccine research for prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 134-139.
[4]	Yongbo Liu, Jia Guo. The research progress of exosomes in the immune escape of prostate cancer cell [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 140-145.
[5]	Jian Yang, Lu Yang. The application prospects of exosomes in the diagnosis of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(02): 146-151.
[6]	Tianlong Luo, Qingqing He, Hai Huang. Long-term comprehensive management of chronic urinary dysfunction and the practice of sustainable rehabilitation [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 21-26.
[7]	Fan Feng, Wenliang Ma, Xiang Dong, Jun Pan, Weidong Gan, Hongqian Guo. An evidence-based analysis in early postoperation： robot-assisted laparoscopic radical prostatectomy combined anterior and posterior approach [J]. Chinese Journal of Endourology(Electronic Edition), 2025, 19(01): 83-87.
[8]	Wei Li, Zijian Song, Yancheng Lai, Rui Zhou, Han Wu, Longxin Deng, Rui Chen. The current state and prospects of artificial intelligence applied to prognosis prediction in prostate cancer patients [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 541-546.
[9]	Wei'an Zhu, Huahui Lin, Jianjie Wu, Jiongduan Huang, Tingting Wu, Wenjie Lai. RDM1 promotes prostate cancer cell progression through CDK4 [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 618-625.
[10]	Gongwei Wang, Shuhao Li, Song Wei, Boran Lyu, Cheng Hu. Study on the killing effect of oncolytic virus M1 on different prostate cancer cells [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 626-632.
[11]	Yihui Shi, Pingxin Zhang, Yong Zhu, Delin Yang. Research progress on positive surgical margins after robot assisted radical prostatectomy [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(06): 633-637.
[12]	Yan Wang, Hongyang Qian, Yinjie Zhu, Baijun Dong, Jiahua Pan, Wei Xue. Preliminary exploration of tumor control effect of robot assisted single port extraperitoneal radical prostatectomy in the treatment of high-risk prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 435-440.
[13]	Jun Zheng, Jieying Wu, Haibo Tan, Anquan Zheng, Tengcheng Li. Construction of EGFR-MEK-TZ combined molecules and it's effects on proliferation and apoptosis of castration-resistant prostate cancer cells [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 503-508.
[14]	Xinzhao Li, Tingtao Zhang, Feng Zhu, Jinshan Liu, Dachuang Liu. The value of fibrinogen, D-dimer and alkaline phosphatase in the diagnosis of bone metastasis of prostate cancer [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 459-463.
[15]	Yongjun Yang, Yiming Zeng, Xianya He, Qiang Lu, Yuanwei Li. Safety and effectiveness of multi-mode image fusion targeted transperineal biopsy technique under local anaesthesia in patients with ASA grade ≥Ⅲ [J]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(05): 441-447.

Please choose a citation manager

Content to export